Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
Seres Therapeutics (Nasdaq: MCRB), a leading live biotherapeutics company, has scheduled a conference call and live audio webcast for May 7, 2025, at 8:30 a.m. ET to discuss their first quarter 2025 financial results and provide business updates.
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 4618787. The webcast will be available in the 'Investors and News' section of the Seres website and will remain archived for approximately 21 days after the event.
Seres Therapeutics (Nasdaq: MCRB), una società leader nel campo dei bioterapici vivi, ha programmato una teleconferenza e una diretta audio webcast per il 7 maggio 2025 alle 8:30 ET per discutere i risultati finanziari del primo trimestre 2025 e fornire aggiornamenti aziendali.
Gli investitori possono partecipare alla teleconferenza chiamando il numero 800-715-9871 (nazionale) o 646-307-1963 (internazionale) con ID conferenza 4618787. La webcast sarà disponibile nella sezione 'Investitori e Notizie' del sito Seres e resterà archiviata per circa 21 giorni dopo l'evento.
Seres Therapeutics (Nasdaq: MCRB), una empresa líder en bioterapéuticos vivos, ha programado una llamada de conferencia y una transmisión de audio en vivo para el 7 de mayo de 2025 a las 8:30 a.m. ET para discutir los resultados financieros del primer trimestre de 2025 y ofrecer actualizaciones comerciales.
Los inversionistas pueden acceder a la llamada de conferencia marcando al 800-715-9871 (nacional) o al 646-307-1963 (internacional) con el ID de conferencia 4618787. La transmisión estará disponible en la sección 'Inversionistas y Noticias' del sitio web de Seres y permanecerá archivada aproximadamente 21 días después del evento.
Seres Therapeutics (나스닥: MCRB)는 선도적인 생물치료제 회사로서 2025년 5월 7일 오전 8시 30분(동부시간)에 2025년 1분기 재무 결과와 사업 현황을 논의하기 위한 컨퍼런스 콜 및 실시간 오디오 웹캐스트를 예정했습니다.
투자자들은 국내 전화번호 800-715-9871 또는 국제 전화번호 646-307-1963에 컨퍼런스 ID 4618787를 입력하여 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트는 Seres 웹사이트의 '투자자 및 뉴스' 섹션에서 시청할 수 있으며, 행사 후 약 21일간 아카이브됩니다.
Seres Therapeutics (Nasdaq : MCRB), une entreprise leader dans le domaine des biothérapies vivantes, a programmé une conférence téléphonique et une diffusion audio en direct pour le 7 mai 2025 à 8h30 ET afin de discuter des résultats financiers du premier trimestre 2025 et de fournir des mises à jour commerciales.
Les investisseurs peuvent accéder à la conférence téléphonique en composant le 800-715-9871 (domestique) ou le 646-307-1963 (international) avec l’identifiant de conférence 4618787. La diffusion sera disponible dans la section « Investisseurs et Actualités » du site Seres et restera archivée pendant environ 21 jours après l’événement.
Seres Therapeutics (Nasdaq: MCRB), ein führendes Unternehmen für lebende Biotherapeutika, hat eine Telefonkonferenz und einen Live-Audio-Webcast für den 7. Mai 2025 um 8:30 Uhr ET angesetzt, um die Finanzergebnisse des ersten Quartals 2025 zu besprechen und Geschäftsaktualisierungen zu geben.
Investoren können an der Telefonkonferenz teilnehmen, indem sie die Nummer 800-715-9871 (national) oder 646-307-1963 (international) mit der Konferenz-ID 4618787 wählen. Der Webcast wird im Bereich „Investoren und Nachrichten“ auf der Seres-Website verfügbar sein und etwa 21 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When will Seres Therapeutics (MCRB) release Q1 2025 earnings?
How can investors join Seres Therapeutics' Q1 2025 earnings call?
How long will MCRB's Q1 2025 earnings webcast be available?
Where can I find Seres Therapeutics' Q1 2025 earnings webcast?
